Venatorx Pharmaceuticals develops novel anti-infectives targeting multi-drug-resistant bacterial and challenging viral infections through advanced drug discovery and development techniques. The company addresses the urgent need for effective treatments in the face of rising antibiotic resistance and limited therapeutic options.
Funding
Funding not disclosed
Founders
Product
Problem
The increasing prevalence of multi-drug-resistant (MDR) bacterial and viral infections poses a significant threat to global health, while the development of new, effective anti-infectives has not kept pace. Current treatment options are limited, leading to higher morbidity and mortality rates, increased healthcare costs, and a growing need for novel therapeutic solutions.
Solution
Venatorx Pharmaceuticals is dedicated to discovering and developing novel anti-infective drugs designed to combat multi-drug-resistant bacterial and hard-to-treat viral infections. The company employs advanced research and development techniques to create innovative therapies that address the urgent need for new treatment options. Their portfolio includes investigational antibiotics and antiviral programs, with a focus on overcoming existing resistance mechanisms and developing new classes of therapeutics. Venatorx's lead asset, cefepime-taniborbactam, has completed Phase 3 clinical trials for complicated urinary tract infections and is under FDA review. The company is also developing an oral BL/BLI antibacterial, ceftibuten-ledaborbactam etzadroxil, slated for Phase 3 trials.
Target Audience
The primary target audience includes healthcare providers, hospitals, and patients in need of effective treatments for multi-drug-resistant bacterial and viral infections.
Features
- Focus on novel chemical approaches to treat multi-drug resistant bacterial and viral infections.
- Cefepime-taniborbactam: An investigational antibiotic that has completed a Phase 3 study for complicated urinary tract infections (cUTI).
- Ceftibuten-ledaborbactam etzadroxil: An oral BL/BLI antibacterial advancing to a global Phase 3 cUTI clinical trial.
- Novel class of non-beta-lactam Penicillin Binding Protein (PBP) inhibitors with the potential to circumvent bacterial resistance.
- Over 120 patents filed, with all investigational molecules discovered internally.